Joyce Okawa
YOU?
Author Swipe
View article: Clinical research: photo validation study using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores in patients with dermatomyositis
Clinical research: photo validation study using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores in patients with dermatomyositis Open
In this study, we evaluated Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores calculated from photos taken by trained clinic staff. We found excellent reliability between photographs and an in-person scoring of the C…
View article: Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial Open
View article: Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of LenabasumTM
Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of LenabasumTM Open
View article: Frequency of immunostimulatory herbal supplement use among patients with autoimmune skin disease
Frequency of immunostimulatory herbal supplement use among patients with autoimmune skin disease Open
View article: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM
Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM Open
View article: Cutaneous lupus concerns from the patient perspective: a qualitative study
Cutaneous lupus concerns from the patient perspective: a qualitative study Open
Objective There is a need to identify concerns unique to patients with cutaneous lupus erythematosus (CLE), which may not be captured by current common-practice dermatological quality-of-life tools. This study formally characterises what b…
View article: Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus
Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus Open
Pemphigus is a debilitating IgG-mediated autoimmune disease requiring better tolerated, more targeted, and rapid onset therapies. ALXN1830 is a humanized IgG4 antibody that blocks neonatal Fc receptor interactions with IgG. A multicenter, …
View article: A prospective cohort study comparing the performance of interferon gamma release assays in autoimmune skin diseases
A prospective cohort study comparing the performance of interferon gamma release assays in autoimmune skin diseases Open
View article: Managing interventional clinical trials in the setting of COVID-19: Experience in an autoimmune skin disease unit
Managing interventional clinical trials in the setting of COVID-19: Experience in an autoimmune skin disease unit Open
View article: Evaluating the effect of prior authorizations in patients with complex dermatologic conditions
Evaluating the effect of prior authorizations in patients with complex dermatologic conditions Open
View article: Supplemental Table 1: Multivariable regression analysis with and without ETDM patients
Supplemental Table 1: Multivariable regression analysis with and without ETDM patients Open
This table identifies risk factors for malignancy associated dermatomyositis (DM) within two years of DM diagnosis. Results show that the classic subtype of DM (CDM) and older age at DM diagnosis are independent risk factors for malignancy…
View article: AB002. Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in pediatric cutaneous lupus among pediatric dermatologists and rheumatologists
AB002. Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in pediatric cutaneous lupus among pediatric dermatologists and rheumatologists Open
BACKGROUND: Cutaneous lupus erythematosus (CLE) refers to skin manifestations of the autoimmune disease lupus erythematosus (LE). While CLE has been extensively researched in the adult population, few studies exist in the pediatric populat…
View article: 610 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated on an open-label extension of trial JBT101-DM-001
610 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated on an open-label extension of trial JBT101-DM-001 Open
View article: 568 The impact of prior authorizations for patients with complex dermatological conditions
568 The impact of prior authorizations for patients with complex dermatological conditions Open
View article: Evaluation of CLASI by paediatric dermatologists and rheumatologists
Evaluation of CLASI by paediatric dermatologists and rheumatologists Open
The term ‘lupus erythematosus’ refers to a range of related disorders. As many as 70–80% of lupus patients will develop skin lesions (abnormal patches) at some point during the course of their disease. Types of lupus affecting the skin are…
View article: 儿科皮肤病专家和风湿病专家对 CLASI 的评估
儿科皮肤病专家和风湿病专家对 CLASI 的评估 Open
术语“红斑狼疮”指的是一系列相关疾病。多达 70–80% 的狼疮患者将在他们疾病进程的一些时间点发生皮损(异常斑片)。影响皮肤的狼疮类型统称为皮肤红斑狼疮(CLE)。皮肤红斑狼疮疾病面积和严重程度指数 (CLASI) 是对 CLE 患者中皮肤症状严重程度进行分类的一种工具。能够准确可靠地测量皮损是监测某种疾病任何改善或恶化的一种重要方式,有助于在临床试验中观察某种治疗是否有效。已知 CLASI 在成人中是一种可靠(准确)的测量手段,但来自美国的研究者们进行了这项研究,以验证…
View article: Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists
Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists Open
CLASI activity measurement showed excellent inter- and intrarater reliability in paediatric CLE and superiority over the PGA. These results demonstrate that the CLASI is a reliable and valid outcome instrument for paediatric CLE.
View article: FRI0470 A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis
FRI0470 A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis Open
View article: SAT0512 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated in an open label extension of trial jbt101-dm-001
SAT0512 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated in an open label extension of trial jbt101-dm-001 Open
View article: Effect of long-term treatment with tumour necrosis factor-α inhibitors on single-dose ultraviolet-induced changes in human skin
Effect of long-term treatment with tumour necrosis factor-α inhibitors on single-dose ultraviolet-induced changes in human skin Open
Tumour necrosis factor (TNF)-α is induced by ultraviolet (UV) light and is important in photoinflammation. 1 Although TNF-α inhibitors are commonly used for various inflammatory disorders like psoriasis, sometimes in combination with photo…
View article: The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy
The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy Open
Treatment of dermatomyositis (DM) is often achieved with a stepwise algorithm. However, the literature lacks quality evidence to support the use of this therapeutic strategy. The result of a stepwise therapeutic strategy in the management …
View article: Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool–Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists
Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool–Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists Open
Summary Background The Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and Cutaneous Assessment Tool–Binary Method (CAT-BM) have been shown to be reliable and valid outcome measures to assess cutaneous disease in adult de…
View article: The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index ( <scp>CDASI</scp> ) among dermatologists, rheumatologists and neurologists
The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index ( <span>CDASI</span> ) among dermatologists, rheumatologists and neurologists Open
Our results confirm the reliability of the CDASI when used by dermatologists and rheumatologists. The data for its use by neurologists were not as robust.
View article: Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis
Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis Open
Pulmonary complications are common in dermatomyositis (DM) and contribute to significant morbidity and mortality1-3. Patients with dermatomyositis and anti-synthethase4, anti-PM/Scl5 or anti-MDA56 antibodies have specific signs (mechanic's…
View article: Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE)
Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE) Open
View article: A cross-sectional study of untreated depression and anxiety in cutaneous lupus erythematosus and dermatomyositis
A cross-sectional study of untreated depression and anxiety in cutaneous lupus erythematosus and dermatomyositis Open
View article: Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change
Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change Open
The CDASI is a valid and responsive measure that can be used to characterize cutaneous dermatomyositis severity and detect improvement in disease activity. Variations in cut-offs may be due to differences in disease severity between the tw…
View article: Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA
Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA Open